Abstract |
Allergic rhinitis (AR) is one of the most common diseases and represents a global health problem, currently affecting up to 30% of the general population, with a continuously increasing prevalence and significant comorbidities and complications. To date, the mainstay of current treatment strategies of AR includes allergen avoidance, pharmacotherapy and allergen-specific immunotherapy, as defined by Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for both adults and children. The aim of this review is to provide an update on all emerging and future therapeutic options for the treatment of AR.
|
Authors | A Licari, A Marseglia, S Caimmi, A Ricci, B Rundo, D Poddighe, A Verrotti, G L Marseglia |
Journal | Journal of biological regulators and homeostatic agents
(J Biol Regul Homeost Agents)
2015 Apr-Jun
Vol. 29
Issue 2 Suppl 1
Pg. 38-46
ISSN: 0393-974X [Print] Italy |
PMID | 26634586
(Publication Type: Journal Article)
|